Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

被引:31
|
作者
Andrews, Louise M. [1 ]
Riva, Natalia [1 ,2 ]
de Winter, Brenda C. [1 ]
Hesselink, Dennis A. [3 ]
de Wildt, Saskia N. [4 ,5 ]
Cransberg, Karlien [6 ]
van Gelder, Teun [1 ,3 ]
机构
[1] Erasmus MC, Univ Med Ctr Rotterdam, Dept Hosp Pharm, NL-3000 CA Rotterdam, Netherlands
[2] Hosp Pediat JP Garrahan, Unidad Farmacocinet Clin, Buenos Aires, DF, Argentina
[3] Erasmus MC, Univ Med Ctr Rotterdam, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[4] Erasmus MC, Sophia Childrens Hosp, Intens Care, NL-3000 CA Rotterdam, Netherlands
[5] Erasmus MC, Sophia Childrens Hosp, Dept Pediat Surg, NL-3000 CA Rotterdam, Netherlands
[6] Erasmus MC, Sophia Childrens Hosp, Div Nephrol, Dept Pediat, NL-3000 CA Rotterdam, Netherlands
关键词
algorithm; ciclosporin; dose; equation; immunosuppressive drugs; kidney; liver; mycophenolic acid; pharmacokinetics; tacrolimus; therapeutic drug monitoring; transplantation; POPULATION PHARMACOKINETIC ANALYSIS; MYCOPHENOLIC-ACID PHARMACOKINETICS; HIV-INFECTED PATIENTS; RENAL-TRANSPLANT; KIDNEY-TRANSPLANTATION; ACUTE REJECTION; CYCLOSPORINE PHARMACOKINETICS; TACROLIMUS CONCENTRATIONS; CALCINEURIN-INHIBITORS; CLINICAL PHARMACOKINETICS;
D O I
10.1517/17425255.2015.1033397
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Starting doses of tacrolimus and ciclosporin are typically chosen on a calculated mg/kg bodyweight basis. After initiation of treatment, doses are adjusted with therapeutic drug monitoring (TDM). This trial-and-error approach has been accepted by most physicians and pharmacists involved in the care of transplanted patients. Areas covered: Dosing algorithms have only fairly recently been proposed to better individualize the starting dose. This review provides an overview of all the currently available dosing algorithms in adult and children for the starting dose of ciclosporin, tacrolimus and mycophenolic acid. In these algorithms, multiple other covariates influencing the starting dose, such as age, hematocrit, comedication and genotype are taken into account. After selecting the starting dose with an algorithm and after initiation of treatment, TDM will, however, remain necessary. Whether or not implementation of such algorithms will improve clinical outcome remains to be demonstrated. Expert opinion: First of all an algorithm needs to be validated, against an independent dataset. Second, in a prospective study the algorithm should prove to reduce the time to reach the target concentration, and to reduce the number of patients with drug concentrations (far) outside the therapeutic window. Finally, a clinical trial demonstrating a benefit on clinical outcome will be crucial in achieving broad acceptance of calculating starting dose using individualized dosing algorithms.
引用
收藏
页码:921 / 936
页数:16
相关论文
共 50 条
  • [1] Individualized dosing algorithms for tacrolimus in kidney transplant recipients: current status and unmet needs
    Schagen, Maaike R.
    Volarevic, Helena
    Francke, Marith I.
    Sassen, Sebastiaan D. T.
    Reinders, Marlies E. J.
    Hesselink, Dennis A.
    de Winter, Brenda C. M.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (07) : 429 - 445
  • [2] Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations
    Zhang, Xiao
    Lin, Guigao
    Tan, Liming
    Li, Jinming
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 102 : 107 - 114
  • [3] Pharmacogenomics and beyond! Customized pharmacotherapy for solid organ transplant recipients
    Lemke, Adley
    Wright, Jessica
    May, Heather
    PHARMACOTHERAPY, 2023, 43 (07): : 596 - 608
  • [4] Generic Maintenance Immunosuppression in Solid Organ Transplant Recipients
    Ensor, Christopher R.
    Trofe-Clark, Jennifer
    Gabardi, Steven
    McDevitt-Potter, Lisa M.
    Shullo, Michael A.
    PHARMACOTHERAPY, 2011, 31 (11): : 1111 - 1129
  • [5] Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients
    Cochrane, Adam B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 : S17 - S21
  • [6] Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients
    Cochrane, Adam B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 : S17 - S21
  • [7] Pharmacologic Issues of Antiretroviral Agents and Immunosuppressive Regimens in HIV-infected Solid Organ Transplant Recipients
    Primeggia, Jennifer
    Timpone, Joseph G., Jr.
    Kumar, Princy N.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2013, 27 (02) : 473 - +
  • [8] Basic immunosuppressive drugs outside solid organ transplantation
    Braun, F
    Behrendt, M
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (03) : 267 - 291
  • [9] New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
    Asberg, A.
    Bjerre, A.
    Neely, M.
    PEDIATRIC TRANSPLANTATION, 2014, 18 (01) : 103 - 111
  • [10] CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation
    Wang, Jian
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2009, 9 (04) : 383 - 390